FY2025 Earnings Estimate for CervoMed Issued By Roth Capital

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Roth Capital reduced their FY2025 earnings estimates for CervoMed in a research note issued on Monday, November 10th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings per share of ($2.96) for the year, down from their previous estimate of ($2.51). Roth Capital currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q4 2025 earnings at ($0.86) EPS, Q1 2026 earnings at ($0.89) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.66) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.83) EPS.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $1.43 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%.

A number of other research firms have also weighed in on CRVO. D. Boral Capital reiterated a “buy” rating and issued a $31.00 price objective on shares of CervoMed in a research note on Tuesday. Zacks Research lowered shares of CervoMed from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. HC Wainwright upgraded shares of CervoMed from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $11.00 to $25.00 in a research note on Wednesday, November 5th. Chardan Capital reissued a “buy” rating and issued a $15.00 price objective on shares of CervoMed in a research note on Monday, August 11th. Finally, Canaccord Genuity Group increased their price objective on shares of CervoMed from $21.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Sell rating to the stock. According to MarketBeat.com, CervoMed currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.86.

CervoMed Stock Up 1.7%

CRVO traded up $0.13 on Thursday, reaching $7.54. 7,544 shares of the company traded hands, compared to its average volume of 1,508,767. CervoMed has a one year low of $1.80 and a one year high of $16.94. The firm has a fifty day simple moving average of $7.99 and a two-hundred day simple moving average of $8.18. The company has a market cap of $69.72 million, a P/E ratio of -2.89 and a beta of -0.89.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after buying an additional 1,526 shares during the period. GSA Capital Partners LLP bought a new stake in shares of CervoMed during the third quarter valued at about $91,000. HighTower Advisors LLC bought a new stake in CervoMed during the first quarter valued at approximately $104,000. Marshall Wace LLP purchased a new stake in shares of CervoMed in the 2nd quarter valued at $76,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of CervoMed in the first quarter worth $110,000. 25.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other CervoMed news, CEO John J. Alam purchased 5,553 shares of the stock in a transaction dated Wednesday, November 12th. The stock was bought at an average price of $7.35 per share, for a total transaction of $40,814.55. Following the transaction, the chief executive officer directly owned 1,467,131 shares in the company, valued at $10,783,412.85. This represents a 0.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO William Robert Elder bought 3,500 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was purchased at an average price of $7.44 per share, for a total transaction of $26,040.00. Following the purchase, the chief financial officer directly owned 9,000 shares in the company, valued at approximately $66,960. This represents a 63.64% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 35.40% of the stock is currently owned by company insiders.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.